Use of antibody drug conjugate

TW202631202AActive Publication Date: 2026-08-01DAIICHI SANKYO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114147943
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2013-12-25
Filing Date
2014-12-25
Publication Date
2026-08-01
Estimated Expiration
2034-12-24

Smart Images

  • Figure TWG2TA001071400_001
    Figure TWG2TA001071400_001
  • Figure TWG2TA001071400_002
    Figure TWG2TA001071400_002
  • Figure TWG2TA001071400_003
    Figure TWG2TA001071400_003
Patent Text Reader

Abstract

The present invention provides an antitumor drug with excellent antitumor efficacy and safety profile, and superior therapeutic effect. An anti-TROP2 antibody is provided, comprising: CDRH1 composed of an amino acid sequence of sequence identification number 23, CDRH2 composed of an amino acid sequence of sequence identification number 24, and CDRH3 composed of an amino acid sequence of sequence identification number 25 in the variable region of its heavy chain; and CDRL1 composed of an amino acid sequence of sequence identification number 26, CDRL2 composed of an amino acid sequence of sequence identification number 27, and CDRL3 composed of an amino acid sequence of sequence identification number 28 in the variable region of its light chain.
Need to check novelty before this filing date? Find Prior Art